INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 432m ago
HOUSE PTR31m ago
SEC 13F31m ago
ROBINHOOD CHAIN31m ago
SEC FORM 4/Option exerciseVerified data

Schmitt Daniel M reported ACTU

Director, President, CEO and Director · ACTUATE THERAPEUTICS, INC. · Common Stock

Side
M
Value
—
Shares
272.1K
Price
—
Executed
Aug 14, 2026
Disclosed
Aug 14, 2026
Disclosure timeline0 days from execution to publication · legal deadline 2 business days
Aug 14 executedAug 14, 2026 disclosed

ACTU · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
21/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Option exercise — administrative, little informational value

  • Relative size+13 / 25

    No reported dollar value · 181.2% of prior position

  • Filing timing0 / 15

    Disclosed 0 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · ACTU

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    82.0K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    48.0K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    36.1K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    269.3K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    82.5K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    133.1K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    126.2K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    82.0K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    65.0K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    65.0K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    126.2K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    87.7K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    368.3K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    195.0K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    824.0K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    682.9K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BI
    BIOS Fund I, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    195.0K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    269.3K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    87.7K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    9
    BF
    BIOS Fund III, LPDirector, 10% Owner
    ACTUACTUATE THERAPEUTICS, INC.
    Grant or award
    		A—
    682.9K sh
    		Oct 28, 2026Oct 30, 2026
    traded Oct 28, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001683168-26-006493
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Aug 14, 2026
    Published
    Aug 14, 2026
    Ingested by INSIDER
    Nov 5, 02:22 UTC
    Last re-read
    Nov 5, 02:22 UTC

    Extracted facts

    Filer
    Schmitt Daniel M
    Role
    Director, President, CEO and Director
    Transaction
    Option exerciseAs filed: “M”
    Asset
    ACTUATE THERAPEUTICS, INC.
    Ticker
    ACTU
    Shares
    272.1K
    Price per share
    $0
    Execution date (reported)
    Aug 14, 2026
    Owned after transaction
    422.2K shares
    Days from execution to publication
    0

    What this establishes

    Schmitt Daniel M filed this Form 4 reporting a option exercise of ACTU on Aug 14, 2026. It became public on Aug 14, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director, President, CEO and Director
    Schmitt Daniel Mcik:0001318470
    Issuer
    ACTUATE THERAPEUTICS, INC.cik:0001652935

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.